Aktiia’s automated Optical Blood Pressure Monitoring System for 24-7 use at the wrist reports accelerating sales growth in the United Kingdom, Ireland, Germany, Austria, Switzerland, France and Italy. The funds will be used to fuel growth in these markets and to obtain FDA clearance.
Distalmotion closed a USD 90 million Series E financing to support global commercialization of its surgical robot Dexter. Revival Healthcare Capital led the round, with participation from 415 Capital and existing investors.
Supira Medical announced a $30 million Series C financing led by Cormorant Asset Management and The Capital Partnership, with participation from 415 Capital, AMED Ventures, PA MedTech VC Fund and Shifamed angel investors.
David Thompson is a co-founder, general partner and chief financial officer of 415C. He has over 35 years of experience in corporate management, audit and finance, including 25 years in medical technology, and has invested in over 20 medical technology companies.
Eduardo Palma is an associate at 415C who joined in September 2021 and has supported due diligence and financing. Palma holds an engineering science degree from the Technical University of Munich and a master's in industrial biotechnology.
Frank Groenewegen is a co-founder and chairman emeritus of 415C with almost 40 years of investing, management, sales and marketing experience in medical technology. He has funded over 40 companies.
Frederik Groenewegen is a co-founder and general partner of 415C who has invested in more than a dozen medical technology companies. Groenewegen led 415C investments in Supira, CorFlow, Cardiac Success, Aktiia, Distalmotion, R3 Vascular and TRiCares.
Linus Rieder is a principal at 415C, where he joined as an associate in July 2019 and has managed dozens of due diligence processes and financings. He is a board observer at R3 Vascular and Cardiac Success.
415C's team has backgrounds in investing, entrepreneurship, biomedical engineering, regulatory affairs, quality control, medicine and medical device commercialization.
415 Capital invests in medical innovation and chronic diseases, with an emphasis on cardio- and neurovascular disorders. Its team provides entrepreneurs with capital, expertise and market access.
415 Capital is a venture capital firm that invests in medical innovation. For over 25 years, its team has provided entrepreneurs with capital, expertise and market access.
415 Capital operates www.415capital.com and states that it protects website users' privacy and complies with applicable data protection provisions, including the European General Data Protection Regulation.
415 Capital
415 CAPITAL: A venture capital firm investing in innovative MedTech companies, focusing on cardiovascular solutions.